First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.

Mikiya Ishihara,Norihito Soga,Takeshi Sasaki,Yasutaka Tono,Hiroshi Shiku,Taizo Shiraishi,Hiroaki Ikeda,Yoshihiro Miyahara,Shinichi Kageyama,Hideki Kanda,Yoshiki Sugimura,Yasuhide Hori,Toshiro Mizuno,Gill Webster ,Naoyuki Katayama ,Norihiro Harada ,Eiichi Satô ,Keiji Uchida

doi:10.1200/jco.2018.36.15_suppl.e15176

First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.

Mikiya Ishihara, Norihito Soga + Show 16 more

https://doi.org/10.1200/jco.2018.36.15_suppl.e15176

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 1

Affiliation: Mie University Hospital, Aichi Cancer Center, Mie University, Nagasaki University, Tokyo Medical University

#MHC Class #Multiple Peptides #Multiple Epitope Peptides #Cholesteryl Pullulan #Multiple Epitope #Epitope Peptides #Cancer Vaccine #Solid Tumors #Clinical Trial

Abstract
Full-Text
Similar Papers

Abstract

Listen

e15176Background: Complexes of Cholesteryl pullulan and NY-ESO-1 antigen (CHP-NY-ESO-1) present multiple epitope peptides to both the MHC class I and class II pathways. MIS416 is a non-toxic microp...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.